Gilead pays unprecedented $125m for Knight priority voucher

Gilead Sciences is paying an unprecedented $125m to acquire Knight Therapeutics' FDA-awarded tropical disease priority review voucher (PRV) – nearly doubling the amount Regeneron and Sanofi put out for a similar PRV earlier this year.